- SEO Test Free Tool

SEO Test Free Tool 2018

Esta herramienta permite analizar el código fuente de una página
y verificar la optimización para los motores de búsquedas.


Respuesta: HTTP/1.1 200 OK
Server: nginx
Date: Sat, 22 Sep 2018 03:54:57 GMT
Content-Type: text/html; charset=UTF-8
Connection: close
Link: ; rel=""
Link: ; rel=shortlink
WPE-Backend: apache
X-Cacheable: SHORT
Vary: Accept-Encoding,Cookie
Cache-Control: max-age=600, must-revalidate
X-Cache: MISS
X-Cache-Group: normal
X-Type: default
Title: Chemical method boosts supply of a key drug compound | Stanford News
Description: Chemists now have a synthetic solution to dwindling supplies of a promising drug for cancer, HIV and possibly other diseases.
Texto: Chemical method boosts supply of a key drug compound | Stanford News Skip to content News Menu Search form Search term Home Find Stories For Journalists Contact October 12, 2017 New method developed by Stanford chemists may replenish dwindling supply of a promising cancer and HIV treatment Supplies of a promising drug for cancer, HIV and possibly other diseases is dwindling, and scientists have struggled to extract more from the marine creatures who produce it. Now, chemists have a synthetic solution. Facebook Twitter Email By Nathan Collins A drug isolated from a marine pest holds promise for treating some of the world’s nastiest diseases, and researchers would love to find out just how effective it is – if only they could get their hands on more. As it stands, the world’s supply of the chemical is down to about half of what it was in the 1990s, and it is hard to extract in sufficient quantities from the feathery sea creatures that produce it. Graduate student Clayton Hardman, left, and postdoctoral scholar Stephen Ho, MD, work in the Wender Lab to create a synthetic supply of an increasingly in-demand drug. (Image credit: L.A. Cicero) Now, Stanford researchers have found a simpler and more efficient way to make this increasingly in-demand compound in the lab, they report October 6 in the journal Science . Their new synthetic supply will be enough to continue ongoing trials testing its effectiveness as a cancer immunotherapy and for treating Alzheimer’s disease and HIV, for which any further supply was until now uncertain. Principal investigator Paul Wender, a professor of chemistry and member of Stanford ChEM-H , said he got so excited about the project at one point, “I put on my lab coat and did some crystallizations,” one of the basic steps of chemistry lab work usually left to students, not full professors. For him, the new paper is the result of decades of work and a happy accident in the Gulf of Mexico almost 50 years ago. From three elephants to a salt shaker Like many other naturally occurring chemicals put into service as pharmaceuticals, bryostatin was discovered following what was essentially a fishing expedition. In the 1960s, having had some success developing drugs from terrestrial flora and fauna, scientists began to shift attention to marine life. Stanford scientists have developed a synthetic substitute for a drug derived from Bugula neritina, or spiral-tufted bryozoan. (Image credit: Fitzgerald Marine Reserve Docent/Creative Commons) The story of bryostatin itself began in 1968, when a marine biologist working in the Gulf of Mexico collected a plethora of marine organisms and sent them to the National Cancer Institute for analysis. One of those organisms, Bugula neritina , a pest best known for fouling up marine environments, showed some promise as an anti-cancer agent. A decade and a half later, researchers reported the structure of the active ingredient, which they dubbed bryostatin 1 after the animal’s common name, brown bryozoan. Unfortunately, bryostatin 1 is very hard to come by. When NCI scientists went back and swept up 14 tons of B. neritina , they managed to extract just 18 grams of bryostatin. “It’s basically three elephants going down to a salt shaker,” Wender said. Worse, subsequent studies showed that B. neritina produces bryostatin only in depths greater than about 10 feet and in warmer seas closer to the equator, and only during certain times of the year. (In fact, the NCI’s 14-ton collection came from California, because subsequent samples from the Gulf of Mexico proved inactive.) And while there was a way to synthesize bryostatin in the lab, it took 57 steps and was not very efficient. Improving on nature Wender and his group have been working with bryostatin analogs – chemicals inspired by bryostatin, but not quite the same – since the 1980s but only recently began thinking about how to make bryostatin itself in a lab. “Ordinarily, we’re in the business of making chemicals that are better than the natural products” such as bryostatin, Wender said. Wender and his lab’s job, in other words, is to come up with chemicals inspired by nature, but more effective. “But when we started to realize that clinical trials a lot of people were thinking about were not being done because they didn’t have enough material, we decided, ‘That’s it, we’re going to roll up our sleeves and make bryostatin because it is now in demand,’” Wender said. Dusting off the lab coat After decades of experience with bryostatin analogs and two years of concerted effort, the lab came up with a much shorter, 29-step process and a yield of 4.8 percent, tens of thousands of times more efficient than extracting bryostatin from B. neritina , and substantially simpler and more efficient than the previous synthetic approach. Graduate student Akira Shimizu uses the rotary evaporator in the Wender lab. (Image credit: L.A. Cicero) “The talent and dedication of this group made possible an achievement which many had thought impossible,” Wender said. “We are so fortunate to have people who are undeterred by that.” The team members have now produced over 2 grams of bryostatin 1, and once production is scaled up, Wender said, they expect manufacturers could produce about 20 grams per year, enough to cover clinical and research needs. That is a bit more than was ever extracted from B. neritina and enough to treat about 20,000 cancer patients or 40,000 Alzheimer’s patients. The results could also be a boon for HIV/AIDS research. In late September, the team reported that a bryostatin 1 analog could help wake latent HIV-infected cells, making them more susceptible to attack by HIV drugs or the immune system. With new insight into – and a new supply of – bryostatin 1, Wender said, “we have an opportunity to start in earnest a clinical conversation about eradicating HIV/AIDS.” Wender is the Francis W. Bergstrom Professor of Chemistry and a member of Stanford Bio-X and the Stanford Cancer Institute . Additional Stanford authors include Clayton Hardman, Stephen Ho, Matthew Jeffreys, Jana Maclaren, Ryan Quiroz, Steven Ryckbosch, Akira Shimizu, Jack Sloane and Matthew Stevens. The research was funded by the National Institutes of Health, the National Science Foundation, the American Cancer Society and the National Cancer Institute. Stanford University has filed a provisional patent application on the technology, which has been licensed by Neurotrope BioScience for the treatment of neurological disorders. An option to license has been granted by Stanford University to Bryologx Inc. for use in HIV/AIDS eradication and cancer immunotherapy. Wender is an adviser to both companies and a co-founder of the latter. Media Contacts Nathan Collins, Stanford News Service: (650) 725-9364, Research Science & Technology Chemistry Health Facebook Twitter Email What to read next: Science & Technology After the Big One: Understanding aftershock risk Geophysicist Gregory Beroza discusses the culprits behind destructive aftershocks and why scientists are harnessing artificial intelligence to gain new insights into earthquake risks. Science & Technology View from above: Using satellite data to study Earth California is embarking on an effort to launch its own satellites to study pollutants – an approach many Stanford researchers have taken advantage of to better understand our changing planet. Campus Life Stanford president urges new students to explore, connect and contribute In a ceremony that marks the beginning of the academic year, Stanford leaders and a Stanford senior encouraged first-year and transfer students to embrace their new community. Stanford Report Receive daily Stanford news. More about Stanford Report For Journalists Press Releases Media Contacts Stanford Experts See Also Contact Stanford News Faculty / Staff Resources Weather 63° Stanford forecast Events Events calendar Stanford News is a publication of Stanford University Communications Stanford Home Maps & Directions Search Stanford Emergency Info Terms of Use Privacy Copyright Trademarks Non-Discrimination Accessibility © Stanford University , Stanford , California 94305 .

1 #content
3 /
8 #
9 #
10 mailto:?subject=An%20interesting%20article%20from%20Stanford%20News&
20 #
21 #
22 mailto:?subject=An%20interesting%20article%20from%20Stanford%20News&
32 /stanford-report/
33 /press-releases/
34 /contact/media-contacts/
35 /experts/
36 /contact/

Otras páginas de analisis SEO :   Woorank en español - Pages Inventory SEO tool - Seo book - Seo Site Checkup

Valid XHTML 1.0 Transitional ¡CSS Válido!
estamos en
publicar avisos